All In Biotech

Drug Trial Radar · NCT07281027

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

Comparing the Effects of Anakinra and Tocilizumab on Outcomes in Patients With New-Onset Refractory Status Epilepticus

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 438 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

438

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Mar 31, 2030

Study completion Sep 30, 2030

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to find out whether two existing medications-anakinra and tocilizumab-can effectively treat a rare and life-threatening brain condition called NORSE (New-Onset Refractory Status Epilepticus). NORSE causes continuous seizures in previously healthy children and adults and does not respond to standard treatments. It often leads to long-term disability or death. Doctors currently use anakinra and tocilizumab as second-line treatments when first-line therapies fail, but there is no clear evidence showing which drug works better or when it should be given. This study aims to answer those questions. The study will enroll patients across 33 hospitals in the United States, Canada, Europe, and Asia. It includes two groups: 1. Randomized Cohort Patients will be randomly assigned to receive either anakinra or tocilizumab within the first 7 days of their illness. Only patients whose doctors were already planning to use one of these medications as part of standard care will be eligible for randomization. Researchers will monitor their recovery and compare outcomes between the two treatments. 2. Observational Cohort Patients who cannot be randomized-usually because they were diagnosed too late-will still be followed to study how the timing of treatment affects recovery. Participants will: * Receive one of the two medications (depending on their group assignment). * Take part in follow-up assessments over the course of one year, including medical evaluations and surveys. Some participants may be followed annually beyond one year. * Optionally participate in a 60-minute interview to share their or their caregiver's experience with NORSE.

Conditions

  • New Onset Refractory Status Epilepticus
  • New-Onset Refractory Status Epilepticus
  • Febrile Infection-Related Epilepsy Syndrome (FIRES)

Interventions

  • AnakinraDrug

    SOC will be followed , Suggested Dose: 10 mg/kg/day IV, divided into 4 daily doses (q6h) Maximum dose: 400 mg/day

  • TocilizumabDrug

    SOC will be followed, Suggested Dose: If \<30 kg: 12 mg/kg IV once every 2 weeks If ≥30 kg: 8 mg/kg IV once every 2 weeks Maximum dose: 800 mg per dose

  • Standard medical treatmentOther

    For patients who could not be randomized by day 7, standard clinical care will be followed and patients will be followed prospectively and observationally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glasgow Outcome Scale - Extended (GOS-E)Time frame: 12 months

Locations

33 sites in 7 countries. Site status is shown where the registry gives one.

  • Barrow Institute

    Phoenix, Arizona

  • Children's Hospital Colorado

    Aurora, Colorado

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Children's National (DC)

    Washington D.C., District of Columbia

  • University of Florida

    Gainesville, Florida

  • University of Chicago

    Chicago, Illinois

  • Northwestern University

    Evanston, Illinois

  • Mass General (MGH)

    Boston, Massachusetts

  • Beth Israel Deaconess

    Boston, Massachusetts

  • Boston Children's Hospital

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • University of Nebraska

    Lincoln, Nebraska

  • New York University

    New York, New York

  • Columbia University

    New York, New York

  • Mount Sinai (NY)

    New York, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Children's Hospital Philadelphia (CHOP)

    Philadelphia, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • UT Southwestern Medical Center

    Dallas, Texas

  • Baylor/Texas Children's

    Houston, Texas

  • Seattle Children's Hospital

    Seattle, Washington

  • University of Wisconsin

    Madison, Wisconsin

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Western University

    London, Canada

  • Hospital for Sick Children

    Toronto, Canada

  • Salpêtrière

    Paris, France

  • University of Modena

    Modena, Italy

  • Seoul National University Hospital

    Seoul, South Korea

  • Karolinska Institute

    Stockholm, Sweden

  • Great Ormond Street Hospital

    London, United Kingdom

  • King's College

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.